- Home
- NGS vs ELDN Comparison
NGS vs ELDN Comparison
Compare NGS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- ELDN
- Stock Information
- Founded
- NGS 1998
- ELDN 2004
- Country
- NGS United States
- ELDN United States
- Employees
- NGS N/A
- ELDN N/A
- Industry
- NGS Oilfield Services/Equipment
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- NGS Energy
- ELDN Health Care
- Exchange
- NGS Nasdaq
- ELDN Nasdaq
- Market Cap
- NGS 326.3M
- ELDN 288.5M
- IPO Year
- NGS 2002
- ELDN N/A
- Fundamental
- Price
- NGS $26.47
- ELDN $4.29
- Analyst Decision
- NGS Strong Buy
- ELDN Strong Buy
- Analyst Count
- NGS 2
- ELDN 1
- Target Price
- NGS $26.50
- ELDN $16.00
- AVG Volume (30 Days)
- NGS 62.2K
- ELDN 229.1K
- Earning Date
- NGS 03-31-2025
- ELDN 03-27-2025
- Dividend Yield
- NGS N/A
- ELDN N/A
- EPS Growth
- NGS 605.21
- ELDN N/A
- EPS
- NGS 1.28
- ELDN N/A
- Revenue
- NGS $152,305,000.00
- ELDN N/A
- Revenue This Year
- NGS $30.81
- ELDN N/A
- Revenue Next Year
- NGS $13.48
- ELDN N/A
- P/E Ratio
- NGS $21.43
- ELDN N/A
- Revenue Growth
- NGS 41.72
- ELDN N/A
- 52 Week Low
- NGS $15.31
- ELDN $1.52
- 52 Week High
- NGS $29.74
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- NGS 45.87
- ELDN 44.28
- Support Level
- NGS $25.45
- ELDN $4.40
- Resistance Level
- NGS $28.13
- ELDN $4.65
- Average True Range (ATR)
- NGS 1.01
- ELDN 0.23
- MACD
- NGS 0.01
- ELDN -0.04
- Stochastic Oscillator
- NGS 39.19
- ELDN 8.16
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.